Treatment Resistant Depression (RP2302E-082423)

August 24, 2023

This 1-hour, in-depth course is designated for general practitioners, psychiatrists, and mental health professionals. This presentation will pose questions raised by the treatment-resistant depressions (TRD) heuristic for biomarker research and engage the audience in addressing the questions of whether biomarker discovery has advanced far enough to be able to prospectively identify TRD, assist with treatment matching, and assess risk.

This is a hybrid event. In-person/On-site registration will be available. All virtual attendees will be emailed the Zoom link the week of the event.

Target Audience

This course is appropriate for general practitioners, psychiatrists, and mental health professionals interested in the management and treatment of depression.

Learning Objectives

  1. Discuss the definition and characteristics of treatment-resistant depression.
  2. Identify and discuss treatment options for individuals with treatment-resistant depression.
  3. Identify brain- and blood-based biomarkers of antidepressant response.
Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
01/02/2023
Course expires: 
02/01/2024
Event starts: 
08/24/2023 - 6:15pm CDT
Event ends: 
08/24/2023 - 7:15pm CDT
Cost:
$0.01
Rating: 
0
Moncrief Cancer Institute (Hybrid)
400 West Magnolia Avenue
Fort Worth, TX
United States
Course Director(s)

Madhukar Trivedi, Madhukar Trivedi, M.D.

has a financial relationship (Independent contractor) with Acadia Pharmaceuticals Inc;.
has a financial relationship (Independent contractor) with Takeda Pharmaceutical Company;.
has a financial relationship (Independent contractor) with Janssen Pharmaceutical;.
has a financial relationship (Independent contractor) with Otsuka America Pharmaceutical;.
has a financial relationship (Independent contractor) with Orexo US Inc;.
has a financial relationship (Independent contractor) with Titan Pharmaceuticals, Inc;.
has a financial relationship (Independent contractor) with Orexo US Inc;.
has a financial relationship (Independent contractor) with Axsome Therapeutics;.
has a financial relationship (Independent contractor) with Merck Sharp & Dohme Corp.;.
has a financial relationship (Independent contractor) with SAGE Therapeutics;.
has a financial relationship (Independent contractor) with Biogen NA;.
has a financial relationship (Independent contractor) with Alto Neuroscience Inc;.
has a financial relationship (Independent contractor) with GreenLight VitalSign6 Inc;.
has a financial relationship (Independent contractor) with Neurocrine Biosciences Inc;.
has a financial relationship (Independent contractor) with Signant Health;.
has a financial relationship (Independent contractor) with Mind Medicine;.
has a financial relationship (Independent contractor) with Legion Health;.
has a financial relationship (Independent contractor) with Alkermes Inc;.
has a financial relationship (Independent contractor) with GH Research Limited;.
has a financial relationship (Independent contractor) with Mind Medicine (MindMed) Inc;.
has a financial relationship (Independent contractor) with SAGE Therapeutics;.
Peer reviewer(s)

Taryn Mayes, Madhukar Trivedi, M.D.

has no relevant financial relationships to disclose at this time.
Speaker(s)

Madhukar Trivedi, Madhukar Trivedi, M.D.

has a financial relationship (Independent contractor) with Axsome Therapeutics;.
has a financial relationship (Independent contractor) with Merck Sharp & Dohme Corp.;.
has a financial relationship (Independent contractor) with SAGE Therapeutics;.
has a financial relationship (Independent contractor) with Titan Pharmaceuticals, Inc;.
has a financial relationship (Independent contractor) with Orexo US Inc;.
has a financial relationship (Independent contractor) with Alto Neuroscience Inc;.
has a financial relationship (Independent contractor) with GreenLight VitalSign6 Inc;.
has a financial relationship (Independent contractor) with Neurocrine Biosciences Inc;.
has a financial relationship (Independent contractor) with Signant Health;.
has a financial relationship (Independent contractor) with Biogen NA;.
has a financial relationship (Independent contractor) with Alkermes Inc;.
has a financial relationship (Independent contractor) with GH Research Limited;.
has a financial relationship (Independent contractor) with Mind Medicine (MindMed) Inc;.
has a financial relationship (Independent contractor) with SAGE Therapeutics;.
has a financial relationship (Independent contractor) with Mind Medicine;.
has a financial relationship (Independent contractor) with Legion Health;.
has a financial relationship (Independent contractor) with Janssen Pharmaceutical;.
has a financial relationship (Independent contractor) with Otsuka America Pharmaceutical;.
has a financial relationship (Independent contractor) with Orexo US Inc;.
has a financial relationship (Independent contractor) with Acadia Pharmaceuticals Inc;.
has a financial relationship (Independent contractor) with Takeda Pharmaceutical Company;.

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.01
Please login or create an account to take this course.

Registration

To register:

  1. Login to your existing account or create an account in EthosCE, online learning management system, by selecting the "create an account" link.
  2. Once logged in, return to this course page, select the designated category and click the "add to cart" button.
  3. In the following "checkout" pages you will review and verify your information. No payment is required.
  4. After your order is submitted your registration will be completed. A confirmation will be sent by email.